Navigation Links
Barrett's esophagus carries lower risk of malignancy than previously reported
Date:6/16/2011

Patients with Barrett's esophagus may have a lower risk of esophageal cancer than previously reported, according to a large, long-term study published online June 16 in the Journal of the National Cancer Institute.

Barrett's esophagus is a premalignant condition, and patients who have it are often advised to have regular endoscopies to watch for signs of esophageal adenocarcinoma, the most common kind of esophageal cancer in many parts of the world. But how often Barrett's esophagus progresses to cancer has not been clear. Previous estimates of the rate of progression have varied widely.

In this study, Shivaram Bhat, B.Ch., MRCP, of Queens University Belfast and colleagues prospectively followed 8,522 patients in the Northern Ireland Barrett's Esophagus Registry, one of the largest registries in the world of people with the condition. After an average follow-up time of 7 years, 79 patients were diagnosed with esophageal cancer, 16 with cancer of the gastric cardia (the part of the stomach closest to the esophagus), and 36 with precancerous changes known as high-grade dysplasia. In the entire group, the incidence of these three conditions combined was 0.22% per year. Previous studies have reported an incidence of cancer among people with Barrett's esophagus between 0.58% and 3% per year.

The researchers also looked at the incidence of cancer and high-grade dysplasia in different subgroups of patients. Men were statistically significantly more likely to progress to malignancy than women, and people age 60-69 had a higher risk than those under 50 or those age 80 and over. The highest rates of progression were among patients with low-grade dysplasia (1.40%) or specialized intestinal metaplasia (0.38%) at their initial endoscopy and biopsy.

The authors conclude that the risk of Barrett's esophagus progressing to esophageal cancer is less than previously reported and that this finding has implications for clinical practice. "Current recommendations for surveillance are based on higher estimates of cancer risk among patients with [Barrett's esophagus] than were seen in this study and therefore, they may not be justified," they write.

In an accompanying editorial, Douglas Corley, M.D., Ph.D., from Kaiser Permanente's research division in Oakland, Calif., notes that the study provides one of the first estimates of incidence of esophageal cancer in people with Barrett's esophagus from a large multicenter population.

He writes that the study provides support "for many paradigms underlying current thoughts about the management of Barrett's esophagus." For instance, people without specialized intestinal metaplasia are at relatively low risk and are less likely to benefit from surveillance or treatment while those with intestinal metaplasia are at increased risk. He notess that the increased risk "may make surveillance cost-effective if surveillance or treatment is effective (an unproved tenet to date)."

Corley adds that the study can "help inform the development of more meaningful "personalized risk scores that incorporate demographic, biochemical, and genetic factors."


'/>"/>

Contact: Kristine Crane
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Cancer Risk With Barretts Esophagus May Be Lower Than Thought
2. Long-term follow-up shows multipolar electrocoagulation ablation effective for Barretts esophagus
3. An international study in China finds strawberries may slow precancerous growth in the esophagus
4. Treatment of Barretts esophagus may lower risk of esophageal cancer
5. Watchful waiting no longer recommended for some high-risk Barretts esophagus patients
6. Extremely obese children have 40 percent higher risk of reflux disease of esophagus
7. New endoscopic treatment may spare Barretts esophagus patients from surgery
8. Prolonging life carries more weight
9. Nationwide Health Information Network now carries public health data
10. Proton therapy carries precise, potent punch against childrens cancers
11. Proton Therapy Carries Precise, Potent Punch Against Cancers for Patients at The Children's Hospital of Philadelphia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... 2017 , ... Kevin Harrington (one of the original Sharks from mega-hit reality ... the topic of Beauty and Personal Care. , Everyone makes New ... to commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting ... Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted ... providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug ...
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, pocket knife, luggage ... Cradle to Cradle Product Design Challenge , the Cradle to Cradle Products Innovation ... circular design challenges scheduled to run through early 2018. The challenges are presented by ...
(Date:1/17/2017)... ... ... SC&H Group, a leading audit, tax, and consulting firm, announced that Chris ... practice . Rossi is the third technology consulting leader to join SC&H Group’s IT ... the practice continues to expand.     , Bringing more than 25 years of business consulting ...
(Date:1/17/2017)... ... January 17, 2017 , ... The Sharie Withers Agency, a ... the latest beneficiary of their thriving community involvement program. The current campaign fundraises ... the dreams of terminally ill patients. Donations to this worthy cause may now ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017 North America ... GlobalData,s new report, "North America Insulin Delivery Market Outlook ... America Insulin Delivery market. The report provides value, in ... prices (USD) within market segments - Insulin Pens, Insulin ... The report also provides company shares and distribution shares ...
(Date:1/17/2017)... 2017 Research and Markets has announced ... - 2024" report to their offering. ... This new report revisits the market ... was issued in May of 2015. Self-healing is an area of ... analysis we projected a market potential of $2.7 billion ($US) by ...
(Date:1/17/2017)... Israel , January 17, 2017 Management ... TyrNovo, Ltd.   KIT-302 Development On Track For ... FDA in Q1 2017   ... Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ; ... update call on Monday, January 23 rd at 8:30am Eastern Time to ...
Breaking Medicine Technology: